- Home
- STTK vs MPV Comparison
STTK vs MPV Comparison
Compare STTK & MPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- MPV
- Stock Information
- Founded
- STTK 2016
- MPV 1988
- Country
- STTK United States
- MPV United States
- Employees
- STTK N/A
- MPV N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- MPV Finance Companies
- Sector
- STTK Health Care
- MPV Finance
- Exchange
- STTK Nasdaq
- MPV Nasdaq
- Market Cap
- STTK 56.8M
- MPV 181.3M
- IPO Year
- STTK 2020
- MPV N/A
- Fundamental
- Price
- STTK $1.12
- MPV $16.35
- Analyst Decision
- STTK Hold
- MPV
- Analyst Count
- STTK 3
- MPV 0
- Target Price
- STTK $2.00
- MPV N/A
- AVG Volume (30 Days)
- STTK 182.2K
- MPV 25.2K
- Earning Date
- STTK 02-27-2025
- MPV 01-01-0001
- Dividend Yield
- STTK N/A
- MPV 8.71%
- EPS Growth
- STTK N/A
- MPV N/A
- EPS
- STTK N/A
- MPV 1.71
- Revenue
- STTK $6,435,000.00
- MPV N/A
- Revenue This Year
- STTK $313.04
- MPV N/A
- Revenue Next Year
- STTK N/A
- MPV N/A
- P/E Ratio
- STTK N/A
- MPV $9.35
- Revenue Growth
- STTK 382.75
- MPV N/A
- 52 Week Low
- STTK $0.94
- MPV $11.18
- 52 Week High
- STTK $11.76
- MPV $16.42
- Technical
- Relative Strength Index (RSI)
- STTK 43.75
- MPV 31.07
- Support Level
- STTK $1.13
- MPV $16.51
- Resistance Level
- STTK $1.39
- MPV $17.38
- Average True Range (ATR)
- STTK 0.11
- MPV 0.37
- MACD
- STTK 0.00
- MPV -0.09
- Stochastic Oscillator
- STTK 18.18
- MPV 2.91
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.